WallStreetZenWallStreetZen

NASDAQ: MGX
Metagenomi Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Metagenomi Therapeutics earnings were -$85.9M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MGX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$23.1M, up 2.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MGX reported annual earnings of -$87.9M, with 12.6% growth. The next MGX earnings date is Aug 11, 2026.

MGX earnings history

Current Revenue
$22.3M
Current Earnings
-$85.9M
Current Profit Margin
-384.6%

MGX Return on Equity

Current Company
-51.2%
Current Industry
-141.9%
Current Market
13.5%
MGX's Return on Equity (-51.2%)... subscribe to Premium to read more.
High Return on Equity Performance

MGX Return on Assets

Current Company
-36.6%
Current Industry
-13.7%
MGX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MGX announces earnings.

MGX Return on Capital Employed

Current Company
-49.32%
Current Industry
-9.6%

MGX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MGX-$75.42M-$85.89MN/A-$2.30
EXOZ-$9.34M-$9.67MN/A-$1.14
DWTX-$28.09M-$28.32MN/A$0.55
IBO-$13.77M-$12.86MN/A-$0.29
ATYR-$68.47M-$70.03MN/A-$0.73
View Top Biotech Stocks

MGX earnings dates

Next earnings date
Aug 11, 2026

Metagenomi Therapeutics Earnings Reports & History FAQ

What were Metagenomi Therapeutics's earnings last quarter?

On MGX's earnings call on Apr 1, 2026, Metagenomi Therapeutics (NASDAQ: MGX) reported Q1 2026 earnings per share (EPS) of -$0.61, up 10.29% year over year. Total MGX earnings for the quarter were -$23.06 million. In the same quarter last year, Metagenomi Therapeutics's earnings per share (EPS) was -$0.68.

If you're new to stock investing, here's how to buy Metagenomi Therapeutics stock.

When does Metagenomi Therapeutics report earnings?

The next MGX earnings call is Aug 11, 2026. Add MGX to your watchlist to be reminded of Metagenomi Therapeutics's next earnings date.

Is Metagenomi Therapeutics profitable or losing money?

As of the last Metagenomi Therapeutics earnings report, Metagenomi Therapeutics is currently losing money. Metagenomi Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$85.89 million, a 10.18% increase year over year.

What was MGX's earnings growth in the past year?

As of Metagenomi Therapeutics's earnings date in Apr 1, 2026, Metagenomi Therapeutics's earnings has grown year over year. MGX earnings in the past year totalled -$85.89 million.

What are Metagenomi Therapeutics's earnings expectations?

The current EPS estimate for Metagenomi Therapeutics's earnings report in Aug 11, 2026 is -$0.63.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.